1) Forest Laboratories, Inc today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.
3) Ablynx receives further milestone payments from Boehringer. Ablynx and Boehringer have entered in strategic alliance for developing Nanobody therapeutics in Oncology and many therapeutic areas (link)
4) Pozen announced approval of VIMOVO (naproxen/ esomeprazole magnesium) and would receive milestone payment from Astrazeneca (link). Note: Pozen already had successfully marketed combination of Sumatriptan/Naproxen combination in collaboration with GSK.